Prosetta's Management


Vishwanath R. Lingappa, MD, PhD

Chief Executive Officer, Chief Technology Officer, and Member of the Board of Directors

Vishwanath R. Lingappa is the Founder, Chief Technology Officer, and CEO of Prosetta Biosciences, Inc, in San Francisco. Since founding the company in 2003, he and his colleagues are responsible for bringing in over $35M through non-dilutive government contracts, while advancing several discovery programs into multi-year licensing and commercial development agreements with pharmaceutical companies such as Bristol-Myers Squibb, AstraZeneca, Elanco, and Takeda.  Dr. Lingappa oversees all research and discovery efforts. In recent years he has expanded Prosetta’s core technology beyond infectious disease, to central nervous system diseases, oncology, and other therapeutic areas. Dr. Lingappa received the B.A. degree with High Honors from Swarthmore College in 1975, the Ph.D. degree from The Rockefeller University in 1979, and the M.D. degree from Cornell University Medical College in 1980. He completed residency training in Internal Medicine before joining the faculty in the Departments of Physiology and Medicine at the University of California, San Francisco (UCSF) in 1982, where he ran an NIH-funded basic research laboratory for over 22 years. It was during this time that the foundational discoveries on which Prosetta’s science is based were made. He has co-authored over 90 publications. He is now an Emeritus Professor of Physiology at UCSF. He is recipient of a Kaiser Award for excellence in teaching (1990) and is a Fellow of the American Association for the Advancement of Science (2004).



Jeff R. Swarz, PhD

Interim Vice President of Business Development

Dr. Swarz brings 28 years of experience in product development and marketing, equity analysis, capital raising, and investment analysis for companies in various segments of the healthcare industry. He is Managing Director and Partner at MM Dillon & Co.Dr. Swarz was a Managing Director at FBR and Life Sciences Group where he was responsible for corporate finance, mergers and acquisitions and private financing. Before that, he was a partner at EGS Healthcare Capital Partners, a healthcare private equity fund investing in biotechnology, specialty pharmaceuticals, and medical device companies. As an equity analyst in biotechnology research at Credit Suisse First Boston and Goldman Sachs, Dr. Swarz was rated among Wall Street's top ten analysts in biotechnology by Institutional Investor Magazine for ten years. Dr. Swarz was a National Institutes of Health Research Fellow in Neurovirology, completed a Postdoctoral Fellowship from Johns Hopkins School of Medicine's Department of Neurology and earned a Ph.D. in Neuroscience from the University of Rochester.